

Commentary

Global equities were mixed yet still positive in July (+2.8%) led by the Healthcare and Technology sectors, while Energy and Consumer Discretionary underperformed. US equities (+4.5%) outperformed amidst the continuation of friendly policy from the US Federal Reserve despite the continued hawkish tones from some members. European equities had a positive month (+4.0%) as the continent continued to reopen from the pandemic.

Asian equities were down (-3.3%) led by Chinese equities (-9.2%) as the government escalated their regulatory crackdown, especially on the Education sector. Japan (+0.8%) underperformed but was stable despite further lockdowns while hosting the Olympics.

Elsewhere, Brent Crude (+1.6% in USD) continued its rally but had a volatile month, while Gold outperformed (+2.5% in USD) and the US Dollar (DXY - 0.3%) was weaker driven by the US macroeconomic backdrop.

Key contributors included:

- Software, notably Microsoft and Oracle. Microsoft delivered strong Q4 2021 FY results with double digit revenue growth in cloud (headlined by 45% growth in Azure revenues), as well as the productivity & business segment while also raising next quarter guidance. Oracle outperformed

on news the Pentagon will meet with the company to assess their eligibility for a US defence cloud contract.

- Frontier Communications in Infrastructure/Property - DM after receiving a buy rating on initiation of broker coverage.
- Consumer Defensive - DM, notably Tesco as the supermarket continues to show strong results relative to peers, and Coca-Cola after reporting strong Q2 revenue growth driven by the ongoing economic recovery.
- Airbus, in the Industrials cluster, after delivering strong results and revising full year guidance amidst an emergence of a recovery in air travel demand.

Key detractors included:

- Internet - Asia/EM, including Chinese internet names including Meituan, Tencent and JD.com as market sentiment waned amidst ongoing regulatory scrutiny of Chinese technology platforms. With growth prospects remaining positive we've taken the opportunity to top up positions in these names.
- Consumer Defensive - Asia/EM, including Wuliangye after an extended period of outperformance, and Ping An as sales have taken time to normalise with insurance policies sold face to face and restrictions still in the process of easing.

Net performance (%)

	Fund	Benchmark	Difference
1 month	-0.8	2.8	-3.7
3 month	0.8	8.9	-8.1
Year to date	8.7	18.7	-10.0
1 year	20.0	29.9	-9.9
3 year p.a.	5.8	14.1	-8.3
5 year p.a.	9.7	14.6	-4.9
Inception p.a.	9.5	12.1	-2.6

Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes

Performance & risk summary¹

Average net exposure	64.5%
Upside capture ratio	74
Downside capture ratio	55
Portfolio standard deviation	8.7%
Benchmark standard deviation	10.6%
Sharpe ratio	1.11


¹All metrics are based on gross of fee returns in AUD terms. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility

Performance contribution² (%)

	1 month
Long	-1.0%
Short	0.1%
Currency	0.2%

²Based on gross returns in AUD

Top & bottom sector contribution^{2,3} (%)



³Antipodes classification

Fund facts

Characteristics

Investment manager	Antipodes Partners
Inception date	1 July 2015
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.20% p.a.
Performance fee	15% of net return in excess of benchmark
Buy/Sell spread	±0.30%
Minimum investment	AUD \$25,000
Distribution	Annual, 30 June

Asset value


Fund AUM	\$3,128m
Strategy AUM	\$6,004m
Unit redemption price	1.7627

Asset allocation⁴

	Equities - Long	Other - Long	Equities - Short	Other - Short
Weight (%)	95.8	0.3	-17.1	-7.6
Count	60	1	28	4
Avg. weight (%)	1.6	0.3	-0.6	-1.9
Top 10 (%)	28.6	-	-11.5	-
Top 30 (%)	67.2	-	-	-

⁴ Call (put) options represented as the current option value (delta adjusted exposure)

Sector exposure^{4,5} (%)




⁵ Antipodes classification

Top 10 equity longs⁴ (%)

Name	Country	Weight
Facebook	United States	4.5
Siemens	Germany	3.5
Microsoft	United States	3.5
Frontier Communications Parent	United States	2.8
Tencent	China/HK	2.7
Taiwan Semiconductor	Taiwan	2.5
Samsung Electronics	Korea	2.5
Ping An Insurance	China/HK	2.2
Tesco	United Kingdom	2.2
Teck Resources	Canada	2.2

Currency exposure^{4,6} (%)



⁶ Where possible, regions, countries and currencies classified on a look through basis

Regional exposure^{4,5,6} (%)

Region	Long	Short	Net
North America	41.2	-12.6	28.6
Western Europe	24.4	-1.3	23.1
- Eurozone	18.4	-1.3	17.1
- United Kingdom	3.5	-	3.5
- Rest Western Europe	2.6	-	2.6
Developed Asia	15.4	-1.6	13.8
- Korea/Taiwan	10.1	-	10.1
- Japan	5.3	-1.6	3.7
Developing Asia	13.3	-1.6	11.8
- China/Hong Kong	12.3	-1.6	10.7
- India	1.1	-	1.1
Australia	1.5	-	1.5
Total Equities	95.8	-17.1	78.8
Other	0.3	-7.6	-
Cash	3.9	-	-
Totals	100.0	-24.6	-

Market cap exposure⁴ (%)

Band	Long	Short	Net
Mega (>\$100b)	52.6	-8.0	44.6
Large (>\$25b <\$100b)	23.9	-2.9	21.0
Medium (>\$5b <\$25b)	16.7	-5.6	11.1
Small (<\$5b)	2.7	-0.7	2.1

Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

Fund features

- Objective to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)

Fund Ratings



Further information

☎ 1300 010 311

✉ invest@antipodespartners.com

Australia Head Office

Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Australia

UK Office

Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK

Disclaimer

This communication is prepared by Antipodes Partners Limited ('Antipodes') ABN 29 602 042 035 AFSL 481580 as the investment manager of the Antipodes Global Fund (ARSN 087 719 515) ('the Fund'). Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 ('PFSL') is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') ABN 22 100 325 184. The Product Disclosure Statement ('PDS') of the Fund is available at www.antipodespartners.com. Any potential investor should consider the PDS before deciding whether to acquire, or continue to hold units in, the Fund.

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance.

Whilst Antipodes, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

The Zenith Investment Partners ("Zenith") Australian Financial Services License No. 226872 rating (assigned November 2020) referred to in this document is limited to "General Advice" (as defined by the Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Zenith usually charges the product issuer, fund manager or a related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessment's and at <https://www.zenithpartners.com.au/RegulatoryGuidelines>.

The Lonsac Ratings (assigned February 2020) presented in this document are published by Lonsac Research presented in this document are published by Lonsac Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsac assumes no obligation to update the relevant documents following publication. Lonsac receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsac's Ratings methodology, please refer to our website at: <https://www.beyond.lonsac.com.au/intelligence/lonsac-ratings>.